Coral Laboratories Ltd

Coral Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 17 Apr 2026, reflecting a nuanced assessment across quality, valuation, financial trends, and technical parameters. Despite ongoing challenges in profitability and sales growth, the company’s valuation and debt profile have improved sufficiently to warrant a less severe rating, though caution remains warranted given recent performance.

Coral Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 March 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 April 2026, providing investors with the most recent and relevant data to assess the stock’s outlook.

Coral Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Coral Laboratories Ltd’s share price reached a fresh 52-week low of Rs.374.95 on 27 March 2026, marking a significant downturn amid a sustained period of negative returns and underperformance relative to its sector and broader market indices.

Coral Laboratories Ltd’s stock price declined to a fresh 52-week low of Rs.378.6 on 25 Mar 2026, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical company’s shares have underperformed both the sector and broader market indices, reflecting persistent challenges in financial performance and market sentiment.

For the third consecutive session, Coral Laboratories Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 387.8 on 24 Mar 2026. This marks a significant drop of 7.64% over the last three days, underscoring persistent selling pressure despite an intraday high of Rs 417 earlier today.

Coral Laboratories Ltd’s share price declined to a fresh 52-week low of Rs.404.95 on 23 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. This new low comes amid a broader market weakness and persistent challenges reflected in the company’s financial performance and valuation metrics.

Coral Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 16 March 2026. This revision reflects deteriorating technical indicators, disappointing financial trends, and persistent valuation concerns, signalling heightened caution for investors amid ongoing underperformance relative to the broader market.

Coral Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 9 March 2026, driven primarily by a shift in technical indicators despite ongoing financial challenges. The company’s Mojo Score now stands at 31.0, reflecting a cautious but improved outlook amid persistent operational headwinds and valuation considerations.

Coral Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 25 Feb 2026, reflecting deteriorating fundamentals and increasingly negative technical signals. The pharmaceutical company’s financial performance has worsened significantly, with declining sales and profits, while technical indicators have shifted towards bearish trends. This comprehensive downgrade is driven by four key parameters: Quality, Valuation, Financial Trend, and Technicals.

Coral Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 20 Feb 2026, primarily driven by a shift in technical indicators despite ongoing financial challenges. The pharmaceutical company’s Mojo Score now stands at 31.0, reflecting a cautious but slightly improved outlook amid persistent operational headwinds and valuation considerations.

Coral Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Feb 2026, reflecting deteriorating fundamentals and increasingly bearish technical indicators. The pharmaceutical company’s financial performance has worsened significantly, with declining sales and profits, while technical analysis signals a negative trend. This comprehensive review examines the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that triggered the rating change.

Coral Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Coral Laboratories Limited, a Vadodara-based pharmaceutical formulations manufacturer, reported deeply disappointing third-quarter results for FY2026, with net profit collapsing 54.70% year-on-year to ₹2.78 crores from ₹6.14 crores in Q3 FY25. The micro-cap pharmaceutical company, with a market capitalisation of ₹173.00 crores, saw its stock trading at ₹479.90 on February 13, down 1.41% on the day and languishing 43.60% below its 52-week high of ₹850.90.

Coral Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 2 February 2026, driven primarily by a shift in technical indicators. Despite persistent financial underperformance and weak long-term growth metrics, the stock’s technical outlook has improved from bearish to mildly bearish, prompting a reassessment of its near-term prospects.

Coral Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 January 2026, providing investors with the latest insights into the company’s performance and outlook.